vosoritide
vosoritide: 7 clinical trials tracked.
vosoritide evidence translation
What we can confirm
7 tracked trials
What it means
What to watch
Prepared research question
What is verified about vosoritide, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (7)
A Multicenter, Randomized, Operationally Seamless Phase 2/3 Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia
Primary endpoint: Phase 2: Predicted Annualized Growth Velocity (AGV) at Week 52 (based on AGV at Weeks 26, 39, and 52 [available cumulative data]
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Vosoritide in Infants and Young Children With Hypochondroplasia, Aged 0 to < 36 Months
Primary endpoint: Incidence of treatment-emergent adverse events
A Phase 3, Open-Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Vosoritide in Children With Hypochondroplasia
Primary endpoint: Evaluate the long-term efficacy of vosoritide treatment until final adult height (FAH)
A Phase 2, Randomized, Multicenter, Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment
Primary endpoint: Change from baseline in Annualized Growth Velocity (AGV)
A Phase 2, Randomized, Controlled, Multicenter Study of Vosoritide in Children With Idiopathic Short Stature
Primary endpoint: Change from baseline in Annualized Growth Velocity (AGV)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vosoritide in Children With Hypochondroplasia
Primary endpoint: Change from baseline in annualized growth velocity (AGV) at Week 52 versus placebo
A Randomized, Controlled, Open-label Clinical Trial With an Open-label Extension to Investigate the Safety of Vosoritide in Infants and Young Children With Achondroplasia at Risk of Requiring Cervicomedullary Decompression Surgery
Primary endpoint: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]